Phathom Pharmaceuticals Inc (NASDAQ: PHAT) kicked off on Friday, down -14.24% from the previous trading day, before settling in for the closing price of $5.90. Over the past 52 weeks, PHAT has traded in a range of $5.07-$19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 1600.29%. While this was happening, its average annual earnings per share was recorded 23.56%. With a float of $38.64 million, this company’s outstanding shares have now reached $68.52 million.
Let’s determine the extent of company efficiency that accounts for 427 employees. In terms of profitability, gross margin is 85.57%, operating margin of -502.18%, and the pretax margin is -605.09%.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Phathom Pharmaceuticals Inc is 44.52%, while institutional ownership is 60.31%. The most recent insider transaction that took place on Jan 21 ’25, was worth 43,371. In this transaction CFO and CBO of this company sold 6,583 shares at a rate of $6.59, taking the stock ownership to the 93,546 shares. Before that another transaction happened on Jan 21 ’25, when Company’s Chief Operating Officer sold 7,886 for $6.59, making the entire transaction worth $51,957. This insider now owns 233,390 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 23.56% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Take a look at Phathom Pharmaceuticals Inc’s (PHAT) current performance indicators. Last quarter, stock had a quick ratio of 4.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.35, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -1.89 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Looking closely at Phathom Pharmaceuticals Inc (NASDAQ: PHAT), its last 5-days average volume was 1.42 million, which is a jump from its year-to-date volume of 1.04 million. As of the previous 9 days, the stock’s Stochastic %D was 44.89%. Additionally, its Average True Range was 0.58.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 0.31%, which indicates a significant decrease from 2.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 94.28% in the past 14 days, which was higher than the 93.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.42, while its 200-day Moving Average is $11.29. However, in the short run, Phathom Pharmaceuticals Inc’s stock first resistance to watch stands at $5.55. Second resistance stands at $6.04. The third major resistance level sits at $6.30. If the price goes on to break the first support level at $4.79, it is likely to go to the next support level at $4.53. Should the price break the second support level, the third support level stands at $4.04.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
The company with the Market Capitalisation of 352.36 million has total of 68,377K Shares Outstanding. Its annual sales at the moment are 680 K in contrast with the sum of -201,590 K annual income. Company’s last quarter sales were recorded 16,350 K and last quarter income was -85,580 K.
